Clinical Trial Details
| Trial ID: | L3140 |
| Source ID: | NCT00675857 |
| Associated Drug: | Nc-503 (Eprodisate Disodium) |
| Title: | A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2|Metabolic Syndrome X |
| Interventions: | DRUG: NC-503 (eprodisate disodium)|OTHER: placebo |
| Outcome Measures: | Primary: Change from baseline to Week 26 in HbA1c levels, 26 weeks | Secondary: Change in HbA1c levels, 26 weeks|The rate of achieving glycemic control, 26 weeks|Change in fasting serum glucose levels, 26 weeks |
| Sponsor/Collaborators: | Sponsor: Bellus Health Inc. - a GSK company |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 200 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT |
| Start Date: | 2008-04 |
| Completion Date: | 2010-05 |
| Results First Posted: | |
| Last Update Posted: | 2010-08-24 |
| Locations: | Calgary, Alberta, T3B 0M3, Canada|Winnipeg, Manitoba, R3E 3P4, Canada|Etobicoke, Ontario, M9R 4E1, Canada|London, Ontario, N6A 4V2, Canada|Oakville, Ontario, L6H 3P1, Canada|Ottawa, Ontario, K1H 1A2, Canada|Ottawa, Ontario, K1K 4L2, Canada|Thornhill, Ontario, L4J 8L7, Canada|Toronto, Ontario, M4R 2G4, Canada|Toronto, Ontario, M5C 2T2, Canada|Chicoutimi, Quebec, G7H 5H6, Canada|Greenfield Park, Quebec, J4V 2H1, Canada|Laval, Quebec, H7T 2P5, Canada|Montreal, Quebec, H1T 2M4, Canada|Montreal, Quebec, H2W 1T7, Canada|Montréal, Quebec, H3A 1A1, Canada|Montréal, Quebec, H3H 2L9, Canada|Montréal, Quebec, H3N 1S4, Canada|Québec, Quebec, G1V 4G5, Canada|Sherbrooke, Quebec, J1G 1B8, Canada|Sherbrooke, Quebec, J1H 5N4, Canada |
| URL: | https://clinicaltrials.gov/show/NCT00675857 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|